

May 27, 2016

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051.

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Intimation under Regulation 30(2) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Please take note that the Board of Directors of the Company, at their meeting held on Friday, May 27, 2016, approved:

- i. Acquisition of M/s Delta Ria and Pathology Private Limited (“**DRPPL**”);
- ii. Acquisition of additional 10% stake in M/s Paliwal Diagnostics Private Limited (“**PDPL**”) and Paliwal Medicare Private Limited (“**PMPL**”).

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided in the **Annexure I** attached to this letter.

We request you to kindly take the same on record.

Thanking You,

Yours faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra
Company Secretary & Legal Head
Encl.: As above

Annexure I

Sr. No.	Particulars in respect of the Event	Details/ Information of the Event		
		DRPPL	PDPL	PMPL
1.	Name of the target entity, details in brief such as size, turnover etc.	Name: Delta Ria and Pathology Private Limited Turnover: As detailed in Point No. 10	Name: Paliwal Diagnostics Private Limited Turnover: As detailed in Point No. 10	Name: Paliwal Medicare Private Limited Turnover: As detailed in Point No. 10
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	No, the transaction is not a related party transaction.	Yes, the transaction is a Related Party Transaction since Paliwal Diagnostics Private Limited is a subsidiary company of Dr. Lal PathLabs Limited and there are two common directors on their Boards. Promoter Group / Promoter do not have any interest in the entity being acquired / additional stake being acquired. The transaction is being carried out at arm's length as per the approval of the Audit Committee.	Yes, the transaction is a Related Party Transaction since Paliwal Medicare Private Limited is a subsidiary company of Dr. Lal PathLabs Limited and there are two common directors on their Boards. Promoter Group / Promoter do not have any interest in the entity being acquired / additional stake being acquired. The transaction is being carried out at arm's length as per the approval of the Audit Committee.
3.	Industry to which the entity being acquired belongs.	Healthcare/ Diagnostics	Healthcare/ Diagnostics	Healthcare/ Diagnostics
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons	The company was under a revenue share arrangement with Dr. Lal	The additional 10% stake in subsidiary company is being acquired pursuant	The additional 10% stake in subsidiary company is being acquired pursuant



	for acquisition of target entity, if its business is outside the main line of business of the listed entity);	PathLabs Limited for the period of 3 years and with the objective of strengthening the presence in the market, it has been decided to acquire 100% stake in the company.	to the Share Purchase Agreement dated August 14, 2008, entered into at the time of initial acquisition.	to the Share Purchase Agreement dated August 14, 2008, entered into at the time of initial acquisition.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No Governmental approvals required.	No Governmental approvals required.	No Governmental approvals required.
6.	Indicative time period for completion of the acquisition	Within 6 month of approvals	Within 6 month of approvals	Within 6 month of approvals
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash	Cash	Cash
8.	Cost of acquisition or the price at which the shares are acquired	Not exceeding INR 8,272.51 per share	Not exceeding INR 65,343 per share	Not exceeding INR 39,439 per share
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	100%	The Company has increased its stake from 70% to 80%	The Company has increased its stake from 70% to 80%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	DRPPL was incorporated on April 13, 2006 in India. Turnover for the last three financial years (Amount in Crores): 2014: INR 1.8 2015: INR 3.1 2016: INR 2.2	PDPL was incorporated on July 8, 1997 in India. Turnover for the last three financial years (Amount in crores): 2014: INR 14.1 2015: INR 15.9 2016: INR 18.7	PMPL was incorporated on April 13, 2006 in India. Turnover for the last three financial years (Amount in crores): 2014: INR 3.1 2015: INR 3.5 2016: INR 3.85

